RAPT Therapeutics Inc (RAPT) Stock Analysis

RAPT Therapeutics Inc (RAPT) is a publicly traded company in the HEALTHCARE sector. It trades at $58.02. This page summarizes the public market data, fundamentals, and frequently asked questions for RAPT, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

RAPT Therapeutics Inc currently has a Bullish sentiment score of 0.21.

About RAPT Therapeutics Inc

RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on revolutionizing treatments for oncology and inflammatory diseases with its oral small molecule therapies. Leveraging a proprietary drug discovery platform that targets key immune regulatory pathways, RAPT is advancing a promising pipeline aimed at addressing critical unmet medical needs. The company is strategically positioned to deliver novel therapeutic options through ...

GNG Research Analysis

GNG Research scores RAPT Therapeutics Inc (RAPT) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for RAPT.

Frequently Asked Questions

Does RAPT pay dividends?

RAPT Therapeutics Inc (RAPT) does not currently pay a regular dividend.